<DOC>
	<DOCNO>NCT01790828</DOCNO>
	<brief_summary>This study describe safety efficacy Xyntha® usual care set .</brief_summary>
	<brief_title>Post Marketing Surveillance To Observe Safety And Efficacy Of Xyntha® In Subjects With Hemophilia A</brief_title>
	<detailed_description>non probability sample</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Patients legally authorize representative pediatric patient agree provide write informed consent form ( data privacy statement ) . Pediatric adult patient treat Xyntha Hemophilia A first approve date KFDA , plan newly prescribe Xyntha . Patients known history hypersensitivity original reformulate Xyntha component product . Patients known history hypersensitivity hamster protein . Patients participate interventional trial investigational drug device .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>